kurskvestЧеловек и его здоровьеHumans and their health1998-57461998-5754Kursk State Medical University10.21626/vestnik/2021-3/07kurskvest-963Research ArticleМЕДИКО-БИОЛОГИЧЕСКИЕ НАУКИMEDICOBIOLOGICAL SCIENCESРоль трансформирующего фактора роста бета в опухолевом процессеRole of transforming growth factor beta in tumor processhttps://orcid.org/0000-0002-5112-6928КукесВладимир ГригорьевичKukesVladimir G.

д-р мед. наук, профессор, академик РАН, руководитель научного направления «Фармакология», НЦЭСМП; профессор кафедры клинической фармакологии и пропедевтики внутренних болезней, Сеченовский Университет

Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences, Head of the Scientific Direction "Pharmacology", SCEEMP; Professor of the Department of Clinical Pharmacology and Propedeutics of Internal Diseases, Sechenov University

elmed@yandex.ruhttps://orcid.org/0000-0001-7024-5546ПрокофьевАлексей БорисовичProkofievAlexey B.

д-р мед. наук, директор Центра клинической фармакологии, НЦЭСМП; профессор кафедры клинической фармакологии и пропедевтики внутренних болезней, Сеченовский Университет

Dr. Sci. (Med.), Director of the Clinical Pharmacology Center, SCEEMP; Professor of the Department of Clinical Pharmacology and Propedeutics of Internal Diseases, Sechenov University

prokofiev@expmed.ruhttps://orcid.org/0000-0002-0079-2832ПарфеноваОльга КонстантиновнаParfenovaOlga K.

лаборант-исследователь

Research Laboratory Assistant

oparfenova22@gmail.comhttps://orcid.org/0000-0003-3855-5899АлександроваТатьяна ВладимировнаAleksandrovaTatyana V.

канд. мед. наук, ст. аналитик

Cand. Sci. (Med.), Senior Analyst

gkb23@yandex.ruhttps://orcid.org/0000-0001-7099-4547ГаздановаАльбина АмырхановнаGazdanovaAlbina A.

канд. мед. наук, доцент кафедры клинической фармакологии и пропедевтики внутренних болезней

Cand. Sci. (Biol.), Associate Professor of the Department of Clinical Pharmacology and Propedeutics of Internal Diseases

gaa71@bk.ruhttps://orcid.org/0000-0001-8353-7863КосенкоВалентина ВладимировнаKosenkoValentina V.

канд. фарм. наук, генеральный директор

Cand. Sci. (Pharm.). Sciences, General Director

kosenko@expmed.ruhttps://orcid.org/0000-0003-4628-5139ТрапковаАлла АркадьевнаTrapkovaAlla A.

канд. биол. наук, зам. генерального директора

Cand. Sci. (Biol.), Deputy General Director

trapkova@expmed.ruНаучный центр экспертизы средств медицинского применения; Первый Московский государственный медицинский университет имени И.М. СеченоваРоссияScientific Centre for Expert Evaluation of Medicinal Products; I.M. Sechenov First Moscow State Medical UniversityRussian FederationНаучный центр экспертизы средств медицинского применения (НЦЭСМП); Первый Московский государственный медицинский университет имени И.М. СеченоваРоссияScientific Centre for Expert Evaluation of Medicinal Products; I.M. Sechenov First Moscow State Medical UniversityRussian FederationНаучно-исследовательский институт биомедицинской химии имени В.Н. ОреховичаРоссияInstitute of Biomedical ChemistryRussian FederationНаучный центр экспертизы средств медицинского примененияРоссияScientific Centre for Expert Evaluation of Medicinal ProductsRussian FederationПервый Московский государственный медицинский университет имени И.М. СеченоваРоссияI.M. Sechenov First Moscow State Medical UniversityRussian Federation2021291120212436169Copyright © Кукес В.Г., Прокофьев А.Б., Парфенова О.К., Александрова Т.В., Газданова А.А., Косенко В.В., Трапкова А.А., 20212021Кукес В.Г., Прокофьев А.Б., Парфенова О.К., Александрова Т.В., Газданова А.А., Косенко В.В., Трапкова А.А.Kukes V.G., Prokofiev A.B., Parfenova O.K., Aleksandrova T.V., Gazdanova A.A., Kosenko V.V., Trapkova A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.kursk-vestnik.ru/jour/article/view/963

Изучение и применение представителей семейства трансформирующего ростового фактора бета (TGF-β) в практической медицине остается актуальной задачей в настоящее время. Более подробное изучение свойств и активности белков, относящихся к TGF-β, открывает новые возможности в лечении и диагностике заболеваний, связанных со скелетной мускулатурой, женской репродуктивной системой, онкологией и сердечно-сосудистой системой, а также в разработке лекарственных средств на их основе. В данной работе рассмотрена роль TGF-β в развитии опухолей и потенциал этого белка в качестве терапевтической мишени, а также сигнальный путь, многообразные белки-маркеры и различные типы рецепторов, включенные в данный процесс. При развитии опухоли TGF-β использует два пути: классический SMAD-зависимый путь и не-SMAD-зависимый путь. На ранних стадиях онкогенеза TGF-β действует как опухолевый супрессор, вызывая цитостатический эффект и апоптоз в нормальных и предзлокачественных клетках. Однако после развития опухоли TGF-β функционирует как промотор опухоли, запускающий переход эпителия в мезенхиму, что приводит к повышенной инвазивности и развитию метастазов. Исследована роль TGF-β при онкогенезе в разных системах органов, в том числе при раке молочных желез, толстой кишки, желудка, гепатоцеллюлярной карциноме, раке щитовидной железе и др. Конкретно TGF-β1 вызывает широкий спектр разных физиологических реакций, регулирует развитие, дифференцировку, канцерогенез и опухолевую прогрессию эпителиальных клеток, оказывает множественное влияние на весь процесс кроветворения. Представлены направления для создания препаратов для лечения опухолей, нацеленные на TGF-β.

The study and application of representatives of the transforming growth factor-beta (TGF-β) family in practical medicine remains an urgent task at the present time. A more detailed study of the properties and activity of proteins related to TGF-β opens up new possibilities in the treatment and diagnosis of diseases associated with skeletal muscles, female reproductive system, oncology and the cardiovascular system, as well as in the development of drugs based on them. This work examines the role of TGF-β in tumor development and the potential of this protein as a therapeutic target, as well as the signaling pathway, various marker proteins, and various types of receptors involved in this process. During tumor development, TGF-β uses two pathways: the classic SMAD-dependent pathway and the non-SMAD-dependent pathway. In the early stages of tumorigenesis, TGF-β acts as a tumor suppressor, causing a cytostatic effect and apoptosis in normal and pre-malignant cells. However, after tumor development, TGF-β functions as a tumor promoter, triggering the transition of the epithelium to the mesenchyme, which leads to increased invasiveness and the development of metastases. The role of TGF-β in oncogenesis in various organ systems has been studied, including in breast, colon, stomach, hepatocellular carcinoma, thyroid cancer, etc. Specifically, TGF-β1 causes a wide range of different physiological reactions, regulates development, differentiation, carcinogenesis and tumor progression of epithelial cells, has multiple effects on the entire process of hematopoiesis. Directions for the creation of drugs for the treatment of tumors targeting TGF-β are presented.

фиброзTGF-βонкологияракSMAD-белкимеханизмы активацииfibrosisTGF-βoncologycancerSMAD proteinsactivation mechanismsReferencesAl Shareef Z., Kardooni H., Murillo-Garzón V., Domenici G., Stylianakis E., Steel J.H., Rabano M., Gorroño-Etxebarria I. et al. Protective effect of stromal Dickkopf-3 in prostate cancer: opposing roles for TGFBI and ECM-1. Oncogene. 2018;37(39):5305-5324. DOI: 10.1038/s41388-018-0294-0Al Shareef Z., Kardooni H., Murillo-Garzón V., Domenici G., Stylianakis E., Steel J.H., Rabano M., Gorroño-Etxebarria I. et al. Protective effect of stromal Dickkopf-3 in prostate cancer: opposing roles for TGFBI and ECM-1. Oncogene. 2018;37(39):5305-5324. DOI: 10.1038/s41388-018-0294-0Benson A.B., Venook A.P., Al-Hawary M.M., Cederquist L., Chen Y.J., Ciombor K.K., Cohen S., Cooper H.S. et al. NCCN Guidelines Insights: Colon Cancer, Version 2.2018. J Natl Compr Canc Netw. 2018;16(4):359-369. DOI: 10.6004/jnccn.2018.0021Benson A.B., Venook A.P., Al-Hawary M.M., Cederquist L., Chen Y.J., Ciombor K.K., Cohen S., Cooper H.S. et al. NCCN Guidelines Insights: Colon Cancer, Version 2.2018. J Natl Compr Canc Netw. 2018;16(4):359-369. DOI: 10.6004/jnccn.2018.0021Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. DOI: 10.3322/caac.21492Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. DOI: 10.3322/caac.21492Cascione M., Leporatti S., Dituri F., Giannelli G. Transforming Growth Factor-β Promotes Morphomechanical Effects Involved in Epithelial to Mesenchymal Transition in Living Hepatocellular Carcinoma. Int J Mol Sci. 2018;20(1):108. DOI: 10.3390/ijms20010108Cascione M., Leporatti S., Dituri F., Giannelli G. Transforming Growth Factor-β Promotes Morphomechanical Effects Involved in Epithelial to Mesenchymal Transition in Living Hepatocellular Carcinoma. Int J Mol Sci. 2018;20(1):108. DOI: 10.3390/ijms20010108Chen K., Wei H., Ling S., Yi C. Expression and significance of transforming growth factor-β1 in epithelial ovarian cancer and its extracellular matrix. Oncol Lett. 2014;8(5):2171-2174. DOI: 10.3892/ol.2014.2448Chen K., Wei H., Ling S., Yi C. Expression and significance of transforming growth factor-β1 in epithelial ovarian cancer and its extracellular matrix. Oncol Lett. 2014;8(5):2171-2174. DOI: 10.3892/ol.2014.2448Chen Y., Huang S., Wu B., Fang J., Zhu M., Sun L., Zhang L., Zhang Y. et al. Transforming growth factor-β1 promotes breast cancer metastasis by downregulating miR-196a-3p expression. Oncotarget. 2017;8(30):49110-49122. DOI: 10.18632/oncotarget.16308Chen Y., Huang S., Wu B., Fang J., Zhu M., Sun L., Zhang L., Zhang Y. et al. Transforming growth factor-β1 promotes breast cancer metastasis by downregulating miR-196a-3p expression. Oncotarget. 2017;8(30):49110-49122. DOI: 10.18632/oncotarget.16308Cheng Y., Guo Y., Zhang Y., You K., Li Z., Geng L. MicroRNA-106b is involved in transforming growth factor β1-induced cell migration by targeting disabled homolog 2 in cervical carcinoma. J Exp Clin Cancer Res. 2016;(35):11. DOI: 10.1186/s13046-016-0290-6Cheng Y., Guo Y., Zhang Y., You K., Li Z., Geng L. MicroRNA-106b is involved in transforming growth factor β1-induced cell migration by targeting disabled homolog 2 in cervical carcinoma. J Exp Clin Cancer Res. 2016;(35):11. DOI: 10.1186/s13046-016-0290-6Dai X., Fang M., Li S., Yan Y., Zhong Y., Du B. miR-21 is involved in transforming growth factor β1-induced chemoresistance and invasion by targeting PTEN in breast cancer. Oncol Lett. 2017;14(6):6929-6936. DOI: 10.3892/ol.2017.7007Dai X., Fang M., Li S., Yan Y., Zhong Y., Du B. miR-21 is involved in transforming growth factor β1-induced chemoresistance and invasion by targeting PTEN in breast cancer. Oncol Lett. 2017;14(6):6929-6936. DOI: 10.3892/ol.2017.7007Fang F., Huang B., Sun S., Xiao M., Guo J., Yi X., Cai J., Wang Z. miR-27a inhibits cervical adenocarcinoma progression by downregulating the TGF-βRI signaling pathway. Cell Death Dis. 2018;9(3):395. DOI: 10.1038/s41419-018-0431-2Fang F., Huang B., Sun S., Xiao M., Guo J., Yi X., Cai J., Wang Z. miR-27a inhibits cervical adenocarcinoma progression by downregulating the TGF-βRI signaling pathway. Cell Death Dis. 2018;9(3):395. DOI: 10.1038/s41419-018-0431-2Geyh S., Rodríguez-Paredes M., Jäger P., Koch A., Bormann F., Gutekunst J., Zilkens C., Germing U. et al. Transforming growth factor β1-mediated functional inhibition of mesenchymal stromal cells in myelodysplastic syndromes and acute myeloid leukemia. Haematologica. 2018;103(9):1462-1471. DOI: 10.3324/haematol.2017.186734Geyh S., Rodríguez-Paredes M., Jäger P., Koch A., Bormann F., Gutekunst J., Zilkens C., Germing U. et al. Transforming growth factor β1-mediated functional inhibition of mesenchymal stromal cells in myelodysplastic syndromes and acute myeloid leukemia. Haematologica. 2018;103(9):1462-1471. DOI: 10.3324/haematol.2017.186734Hata A., Chen Y.G. TGF-β Signaling from Receptors to Smads. Cold Spring Harb Perspect Biol. 2016;8(9):a022061. DOI: 10.1101/cshperspect.a022061Hata A., Chen Y.G. TGF-β Signaling from Receptors to Smads. Cold Spring Harb Perspect Biol. 2016;8(9):a022061. DOI: 10.1101/cshperspect.a022061He B., Xu T., Pan B., Pan Y., Wang X., Dong J., Sun H., Xu X. et al. Polymorphisms of TGFBR1, TLR4 are associated with prognosis of gastric cancer in a Chinese population. Cancer Cell Int. 2018;(18):191. DOI: 10.1186/s12935-018-0682-0He B., Xu T., Pan B., Pan Y., Wang X., Dong J., Sun H., Xu X. et al. Polymorphisms of TGFBR1, TLR4 are associated with prognosis of gastric cancer in a Chinese population. Cancer Cell Int. 2018;(18):191. DOI: 10.1186/s12935-018-0682-0Huang F., Wan J., Hu W., Hao S. Enhancement of Anti-Leukemia Immunity by Leukemia-Derived Exosomes Via Downregulation of TGF-β1 Expression. Cell Physiol Biochem. 2017;44(1):240-254. DOI: 10.1159/000484677Huang F., Wan J., Hu W., Hao S. Enhancement of Anti-Leukemia Immunity by Leukemia-Derived Exosomes Via Downregulation of TGF-β1 Expression. Cell Physiol Biochem. 2017;44(1):240-254. DOI: 10.1159/000484677Ji M., Shi H., Xie Y., Zhao Z., Li S., Chang C., Cheng X., Li Y. Ubiquitin specific protease 22 promotes cell proliferation and tumor growth of epithelial ovarian cancer through synergy with transforming growth factor β1. Oncol Rep. 2015;33(1):133-140. DOI: 10.3892/or.2014.3580Ji M., Shi H., Xie Y., Zhao Z., Li S., Chang C., Cheng X., Li Y. Ubiquitin specific protease 22 promotes cell proliferation and tumor growth of epithelial ovarian cancer through synergy with transforming growth factor β1. Oncol Rep. 2015;33(1):133-140. DOI: 10.3892/or.2014.3580Jiang F., Mu J., Wang X., Ye X., Si L., Ning S., Li Z., Li Y. The repressive effect of miR-148a on TGF beta-SMADs signal pathway is involved in the glabridin-induced inhibition of the cancer stem cells-like properties in hepatocellular carcinoma cells. PLoS One. 2014;9(5):e96698. DOI: 10.1371/journal.pone.0096698Jiang F., Mu J., Wang X., Ye X., Si L., Ning S., Li Z., Li Y. The repressive effect of miR-148a on TGF beta-SMADs signal pathway is involved in the glabridin-induced inhibition of the cancer stem cells-like properties in hepatocellular carcinoma cells. PLoS One. 2014;9(5):e96698. DOI: 10.1371/journal.pone.0096698Jiang F., Yu Q., Chu Y., Zhu X., Lu W., Liu Q., Wang Q. MicroRNA-98-5p inhibits proliferation and metastasis in non-small cell lung cancer by targeting TGFBR1. Int J Oncol. 2019;54(1):128-138. DOI: 10.3892/ijo.2018.4610Jiang F., Yu Q., Chu Y., Zhu X., Lu W., Liu Q., Wang Q. MicroRNA-98-5p inhibits proliferation and metastasis in non-small cell lung cancer by targeting TGFBR1. Int J Oncol. 2019;54(1):128-138. DOI: 10.3892/ijo.2018.4610Jiang W., Xu Z., Yu L., Che J., Zhang J., Yang J. MicroRNA-144-3p suppressed TGF-β1-induced lung cancer cell invasion and adhesion by regulating the Src-Akt-Erk pathway. Cell Biol Int. 2019. DOI: 10.1002/cbin.11158Jiang W., Xu Z., Yu L., Che J., Zhang J., Yang J. MicroRNA-144-3p suppressed TGF-β1-induced lung cancer cell invasion and adhesion by regulating the Src-Akt-Erk pathway. Cell Biol Int. 2019. DOI: 10.1002/cbin.11158Li C., Zhou D., Hong H., Yang S., Zhang L., Li S., Hu P., Ren H. et al. TGFβ1- miR-140-5p axis mediated up-regulation of Flap Endonuclease 1 promotes epithelial-mesenchymal transition in hepatocellular carcinoma. Aging (Albany NY). 2019;11(15):5593-5612. DOI: 10.18632/aging.102140Li C., Zhou D., Hong H., Yang S., Zhang L., Li S., Hu P., Ren H. et al. TGFβ1- miR-140-5p axis mediated up-regulation of Flap Endonuclease 1 promotes epithelial-mesenchymal transition in hepatocellular carcinoma. Aging (Albany NY). 2019;11(15):5593-5612. DOI: 10.18632/aging.102140Li L., Yan S., Zhang H., Zhang M., Huang G., Chen M. Interaction of hnRNP K with MAP 1B-LC1 promotes TGF-β1-mediated epithelial to mesenchymal transition in lung cancer cells. BMC Cancer. 2019;19(1):894. DOI: 10.1186/s12885-019-6119-xLi L., Yan S., Zhang H., Zhang M., Huang G., Chen M. Interaction of hnRNP K with MAP 1B-LC1 promotes TGF-β1-mediated epithelial to mesenchymal transition in lung cancer cells. BMC Cancer. 2019;19(1):894. DOI: 10.1186/s12885-019-6119-xLi M.Y., Liu J.Q., Chen D.P., Li Z.Y., Qi B., Yin W.J., He L. p68 prompts the epithelial-mesenchymal transition in cervical cancer cells by transcriptionally activating the TGF-β1 signaling pathway. Oncol Lett. 2018;15(2):2111-2116. DOI: 10.3892/ol.2017.7552Li M.Y., Liu J.Q., Chen D.P., Li Z.Y., Qi B., Yin W.J., He L. p68 prompts the epithelial-mesenchymal transition in cervical cancer cells by transcriptionally activating the TGF-β1 signaling pathway. Oncol Lett. 2018;15(2):2111-2116. DOI: 10.3892/ol.2017.7552Li T., Zhao N., Lu J., Zhu Q., Liu X., Hao F., Jiao X. Epigallocatechin gallate (EGCG) suppresses epithelial-Mesenchymal transition (EMT) and invasion in anaplastic thyroid carcinoma cells through blocking of TGF-β1/Smad signaling pathways. Bioengineered. 2019;10(1):282-291. DOI: 10.1080/21655979.2019.1632669Li T., Zhao N., Lu J., Zhu Q., Liu X., Hao F., Jiao X. Epigallocatechin gallate (EGCG) suppresses epithelial-Mesenchymal transition (EMT) and invasion in anaplastic thyroid carcinoma cells through blocking of TGF-β1/Smad signaling pathways. Bioengineered. 2019;10(1):282-291. DOI: 10.1080/21655979.2019.1632669Li Y., Chen D., Hao F.Y., Zhang KJ. Targeting TGF-β1 and AKT signal on growth and metastasis of anaplastic thyroid cancer cell in vivo. Eur Rev Med Pharmacol Sci. 2020;24(13):7208. DOI: 10.26355/eurrev_202007_21859Li Y., Chen D., Hao F.Y., Zhang KJ. Targeting TGF-β1 and AKT signal on growth and metastasis of anaplastic thyroid cancer cell in vivo. Eur Rev Med Pharmacol Sci. 2020;24(13):7208. DOI: 10.26355/eurrev_202007_21859Luyimbazi D., Nelson R.A., Choi A.H., Li L., Chao J., Sun V., Hamner J.B., Kim J. Estimates of conditional survival in gastric cancer reveal a reduction of racial disparities with long-term follow-up. J Gastrointest Surg. 2015;19(2):251-257. DOI: 10.1007/s11605-014-2688-9Luyimbazi D., Nelson R.A., Choi A.H., Li L., Chao J., Sun V., Hamner J.B., Kim J. Estimates of conditional survival in gastric cancer reveal a reduction of racial disparities with long-term follow-up. J Gastrointest Surg. 2015;19(2):251-257. DOI: 10.1007/s11605-014-2688-9Ma W., Qin Y., Chapuy B., Lu C. LRRC33 is a novel binding and potential regulating protein of TGF-β1 function in human acute myeloid leukemia cells. PLoS One. 2019;14(10):e0213482. DOI: 10.1371/journal.pone.0213482.Ma W., Qin Y., Chapuy B., Lu C. LRRC33 is a novel binding and potential regulating protein of TGF-β1 function in human acute myeloid leukemia cells. PLoS One. 2019;14(10):e0213482. DOI: 10.1371/journal.pone.0213482.Maishi N., Hida K. Tumor endothelial cells accelerate tumor metastasis. Cancer Sci. 2017;108(10):1921-1926. DOI: 10.1111/cas.13336Maishi N., Hida K. Tumor endothelial cells accelerate tumor metastasis. Cancer Sci. 2017;108(10):1921-1926. DOI: 10.1111/cas.13336Meng X.M., Nikolic-Paterson D.J., Lan H.Y. TGF-β: the master regulator of fibrosis. Nat Rev Nephrol. 2016;12(6):325-338. DOI: 10.1038/nrneph.2016.48Meng X.M., Nikolic-Paterson D.J., Lan H.Y. TGF-β: the master regulator of fibrosis. Nat Rev Nephrol. 2016;12(6):325-338. DOI: 10.1038/nrneph.2016.48Nursal A.F., Pehlivan M., Sahin H.H., Pehlivan S. The Associations of IL-6, IFN-γ, TNF-α, IL-10, and TGF-β1 Functional Variants with Acute Myeloid Leukemia in Turkish Patients. Genet Test Mol Biomarkers. 2016;20(9):544-551. DOI: 10.1089/gtmb.2016.0036Nursal A.F., Pehlivan M., Sahin H.H., Pehlivan S. The Associations of IL-6, IFN-γ, TNF-α, IL-10, and TGF-β1 Functional Variants with Acute Myeloid Leukemia in Turkish Patients. Genet Test Mol Biomarkers. 2016;20(9):544-551. DOI: 10.1089/gtmb.2016.0036Papageorgis P. TGFβ Signaling in Tumor Initiation, Epithelial-to-Mesenchymal Transition, and Metastasis. J Oncol. 2015;(2015):587193. DOI: 10.1155/2015/587193Papageorgis P. TGFβ Signaling in Tumor Initiation, Epithelial-to-Mesenchymal Transition, and Metastasis. J Oncol. 2015;(2015):587193. DOI: 10.1155/2015/587193Parichatikanond W., Luangmonkong T., Mangmool S., Kurose H. Therapeutic Targets for the Treatment of Cardiac Fibrosis and Cancer: Focusing on TGF-β Signaling. Front Cardiovasc Med. 2020;(7):34. DOI: 10.3389/fcvm.2020.00034Parichatikanond W., Luangmonkong T., Mangmool S., Kurose H. Therapeutic Targets for the Treatment of Cardiac Fibrosis and Cancer: Focusing on TGF-β Signaling. Front Cardiovasc Med. 2020;(7):34. DOI: 10.3389/fcvm.2020.00034Peng L., Yuan X.Q., Zhang C.Y., Ye F., Zhou H.F., Li W.L., Liu Z.Y., Zhang Y.Q. et al. High TGF-β1 expression predicts poor disease prognosis in hepatocellular carcinoma patients. Oncotarget. 2017;8(21):34387-34397. DOI: 10.18632/oncotarget.16166Peng L., Yuan X.Q., Zhang C.Y., Ye F., Zhou H.F., Li W.L., Liu Z.Y., Zhang Y.Q. et al. High TGF-β1 expression predicts poor disease prognosis in hepatocellular carcinoma patients. Oncotarget. 2017;8(21):34387-34397. DOI: 10.18632/oncotarget.16166Qu Z., Feng J., Pan H., Jiang Y., Duan Y., Fa Z. Exosomes derived from HCC cells with different invasion characteristics mediated EMT through TGF-β/Smad signaling pathway. Onco Targets Ther. 2019;(12):6897-6905. DOI: 10.2147/OTT.S209413Qu Z., Feng J., Pan H., Jiang Y., Duan Y., Fa Z. Exosomes derived from HCC cells with different invasion characteristics mediated EMT through TGF-β/Smad signaling pathway. Onco Targets Ther. 2019;(12):6897-6905. DOI: 10.2147/OTT.S209413Rouce R.H., Shaim H., Sekine T., Weber G., Ballard B., Ku S., Barese C., Murali V. et al. The TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia. Leukemia. 2016;30(4):800-811. DOI: 10.1038/leu.2015.327Rouce R.H., Shaim H., Sekine T., Weber G., Ballard B., Ku S., Barese C., Murali V. et al. The TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia. Leukemia. 2016;30(4):800-811. DOI: 10.1038/leu.2015.327Sabbadini F., Bertolini M., De Matteis S., Mangiameli D., Contarelli S., Pietrobono S., Melisi D. The Multifaceted Role of TGF-β in Gastrointestinal Tumors. Cancers (Basel). 2021;13(16):3960. DOI: 10.3390/cancers13163960Sabbadini F., Bertolini M., De Matteis S., Mangiameli D., Contarelli S., Pietrobono S., Melisi D. The Multifaceted Role of TGF-β in Gastrointestinal Tumors. Cancers (Basel). 2021;13(16):3960. DOI: 10.3390/cancers13163960Shuang Z.Y., Wu W.C., Xu J., Lin G., Liu Y.C., Lao X.M., Zheng L., Li S. Transforming growth factor-β1-induced epithelial-mesenchymal transition generates ALDH-positive cells with stem cell properties in cholangiocarcinoma. Cancer Lett. 2014;354(2): 320-328. DOI: 10.1016/j.canlet.2014.08.030Shuang Z.Y., Wu W.C., Xu J., Lin G., Liu Y.C., Lao X.M., Zheng L., Li S. Transforming growth factor-β1-induced epithelial-mesenchymal transition generates ALDH-positive cells with stem cell properties in cholangiocarcinoma. Cancer Lett. 2014;354(2): 320-328. DOI: 10.1016/j.canlet.2014.08.030Sun S.L., Wang X.Y. TGF-β1 promotes proliferation and invasion of hepatocellular carcinoma cell line HepG2 by activating GLI-1 signaling. Eur Rev Med Pharmacol Sci. 2018;22(22):7688-7695. DOI: 10.26355/eurrev_201811_16389Sun S.L., Wang X.Y. TGF-β1 promotes proliferation and invasion of hepatocellular carcinoma cell line HepG2 by activating GLI-1 signaling. Eur Rev Med Pharmacol Sci. 2018;22(22):7688-7695. DOI: 10.26355/eurrev_201811_16389Takeuchi Y., Nishikawa H. Roles of regulatory T cells in cancer immunity. Int Immunol. 2016;28(8):401-419. DOI: 10.1093/intimm/dxw025Takeuchi Y., Nishikawa H. Roles of regulatory T cells in cancer immunity. Int Immunol. 2016;28(8):401-419. DOI: 10.1093/intimm/dxw025Tang Y.H., He G.L., Huang S.Z., Zhong K.B., Liao H., Cai L., Gao Y., Peng ZW. et al. The long noncoding RNA AK002107 negatively modulates miR-140-5p and targets TGFBR1 to induce epithelial-mesenchymal transition in hepatocellular carcinoma. Mol Oncol. 2019;13(5):1296-1310. DOI: 10.1002/1878-0261.12487Tang Y.H., He G.L., Huang S.Z., Zhong K.B., Liao H., Cai L., Gao Y., Peng ZW. et al. The long noncoding RNA AK002107 negatively modulates miR-140-5p and targets TGFBR1 to induce epithelial-mesenchymal transition in hepatocellular carcinoma. Mol Oncol. 2019;13(5):1296-1310. DOI: 10.1002/1878-0261.12487Teng Y., Zhao L., Zhang Y., Chen W., Li X. Id-1, a protein repressed by miR-29b, facilitates the TGFβ1-induced epithelial-mesenchymal transition in human ovarian cancer cells. Cell Physiol Biochem. 2014;33(3):717-730. DOI: 10.1159/000358647Teng Y., Zhao L., Zhang Y., Chen W., Li X. Id-1, a protein repressed by miR-29b, facilitates the TGFβ1-induced epithelial-mesenchymal transition in human ovarian cancer cells. Cell Physiol Biochem. 2014;33(3):717-730. DOI: 10.1159/000358647Tu S., Huang W., Huang C., Luo Z., Yan X. Contextual Regulation of TGF-β Signaling in Liver Cancer. Cells. 2019;8(10):1235. DOI: 10.3390/cells8101235Tu S., Huang W., Huang C., Luo Z., Yan X. Contextual Regulation of TGF-β Signaling in Liver Cancer. Cells. 2019;8(10):1235. DOI: 10.3390/cells8101235Vander Ark A., Cao J., Li X. TGF-β receptors: In and beyond TGF-β signaling. Cell Signal. 2018;(52): 112-120. DOI: 10.1016/j.cellsig.2018.09.002Vander Ark A., Cao J., Li X. TGF-β receptors: In and beyond TGF-β signaling. Cell Signal. 2018;(52): 112-120. DOI: 10.1016/j.cellsig.2018.09.002Wang J., Xiang H., Lu Y., Wu T. Role and clinical significance of TGF-β1 and TGF-βR1 in malignant tumors (Review). Int J Mol Med. 2021;47(4):55. DOI: 10.3892/ijmm.2021.4888Wang J., Xiang H., Lu Y., Wu T. Role and clinical significance of TGF-β1 and TGF-βR1 in malignant tumors (Review). Int J Mol Med. 2021;47(4):55. DOI: 10.3892/ijmm.2021.4888Wongnoppavich A., Dukaew N., Choonate S., Chairatvit K. Upregulation of maspin expression in human cervical carcinoma cells by transforming growth factor β1 through the convergence of Smad and non-Smad signaling pathways. Oncol Lett. 2017;13(5):3646-3652. DOI: 10.3892/ol.2017.5939Wongnoppavich A., Dukaew N., Choonate S., Chairatvit K. Upregulation of maspin expression in human cervical carcinoma cells by transforming growth factor β1 through the convergence of Smad and non-Smad signaling pathways. Oncol Lett. 2017;13(5):3646-3652. DOI: 10.3892/ol.2017.5939Wrana J.L. Signaling by the TGFβ superfamily. Cold Spring Harb Perspect Biol. 2013;5(10):a011197. DOI: 10.1101/cshperspect.a011197Wrana J.L. Signaling by the TGFβ superfamily. Cold Spring Harb Perspect Biol. 2013;5(10):a011197. DOI: 10.1101/cshperspect.a011197Wu M., Chen X., Lou J., Zhang S., Zhang X., Huang L., Sun R., Huang P. et al. TGF-β1 contributes to CD8+ Treg induction through p38 MAPK signaling in ovarian cancer microenvironment. Oncotarget. 2016;7(28):44534-44544. DOI: 10.18632/oncotarget.10003Wu M., Chen X., Lou J., Zhang S., Zhang X., Huang L., Sun R., Huang P. et al. TGF-β1 contributes to CD8+ Treg induction through p38 MAPK signaling in ovarian cancer microenvironment. Oncotarget. 2016;7(28):44534-44544. DOI: 10.18632/oncotarget.10003Wu M.Y., Hill C.S. Tgf-beta superfamily signaling in embryonic development and homeostasis. Dev Cell. 2009;16(3):329-343. DOI: 10.1016/j.devcel.2009.02.012Wu M.Y., Hill C.S. Tgf-beta superfamily signaling in embryonic development and homeostasis. Dev Cell. 2009;16(3):329-343. DOI: 10.1016/j.devcel.2009.02.012Yang L., Yu Y., Xiong Z., Chen H., Tan B., Hu H. Downregulation of SEMA4C Inhibit Epithelial-Mesenchymal Transition (EMT) and the Invasion and Metastasis of Cervical Cancer Cells via Inhibiting Transforming Growth Factor-beta 1 (TGF-β1)-Induced Hela cells p38 Mitogen-Activated Protein Kinase (MAPK) Activation. Med Sci Monit. 2020;(26):e918123. DOI: 10.12659/MSM.918123Yang L., Yu Y., Xiong Z., Chen H., Tan B., Hu H. Downregulation of SEMA4C Inhibit Epithelial-Mesenchymal Transition (EMT) and the Invasion and Metastasis of Cervical Cancer Cells via Inhibiting Transforming Growth Factor-beta 1 (TGF-β1)-Induced Hela cells p38 Mitogen-Activated Protein Kinase (MAPK) Activation. Med Sci Monit. 2020;(26):e918123. DOI: 10.12659/MSM.918123Yang Y., Ye W.L., Zhang R.N., He X.S., Wang J.R., Liu Y.X., Wang Y., Yang X.M. et al. The Role of TGF-β Signaling Pathways in Cancer and Its Potential as a Therapeutic Target. Evid Based Complement Alternat Med. 2021;(2021):6675208. DOI: 10.1155/2021/6675208Yang Y., Ye W.L., Zhang R.N., He X.S., Wang J.R., Liu Y.X., Wang Y., Yang X.M. et al. The Role of TGF-β Signaling Pathways in Cancer and Its Potential as a Therapeutic Target. Evid Based Complement Alternat Med. 2021;(2021):6675208. DOI: 10.1155/2021/6675208Yao S., Tian C., Ding Y., Ye Q., Gao Y., Yang N., Li Q. Down-regulation of Krüppel-like factor-4 by microRNA-135a-5p promotes proliferation and metastasis in hepatocellular carcinoma by transforming growth factor-β1. Oncotarget. 2016;7(27): 42566-42578. DOI: 10.18632/oncotarget.9934Yao S., Tian C., Ding Y., Ye Q., Gao Y., Yang N., Li Q. Down-regulation of Krüppel-like factor-4 by microRNA-135a-5p promotes proliferation and metastasis in hepatocellular carcinoma by transforming growth factor-β1. Oncotarget. 2016;7(27): 42566-42578. DOI: 10.18632/oncotarget.9934Ye Z., Zhao L., Li J., Chen W., Li X. miR-30d Blocked Transforming Growth Factor β1-Induced Epithelial-Mesenchymal Transition by Targeting Snail in Ovarian Cancer Cells. Int J Gynecol Cancer. 2015;25(9):1574-1581. DOI: 10.1097/IGC.0000000000000546Ye Z., Zhao L., Li J., Chen W., Li X. miR-30d Blocked Transforming Growth Factor β1-Induced Epithelial-Mesenchymal Transition by Targeting Snail in Ovarian Cancer Cells. Int J Gynecol Cancer. 2015;25(9):1574-1581. DOI: 10.1097/IGC.0000000000000546Yin Q., Liu S., Dong A., Mi X., Hao F., Zhang K. Targeting Transforming Growth Factor-Beta1 (TGF-β1) Inhibits Tumorigenesis of Anaplastic Thyroid Carcinoma Cells Through ERK1/2-NFκkB-PUMA Signaling. Med Sci Monit. 2016;(22):2267-2277. DOI: 10.12659/msm.898702Yin Q., Liu S., Dong A., Mi X., Hao F., Zhang K. Targeting Transforming Growth Factor-Beta1 (TGF-β1) Inhibits Tumorigenesis of Anaplastic Thyroid Carcinoma Cells Through ERK1/2-NFκkB-PUMA Signaling. Med Sci Monit. 2016;(22):2267-2277. DOI: 10.12659/msm.898702Zhang C., Chen B., Jiao A., Li F., Sun N., Zhang G., Zhang J. miR-663a inhibits tumor growth and invasion by regulating TGF-β1 in hepatocellular carcinoma. BMC Cancer. 2018;18(1):1179. DOI: 10.1186/s12885-018-5016-zZhang C., Chen B., Jiao A., Li F., Sun N., Zhang G., Zhang J. miR-663a inhibits tumor growth and invasion by regulating TGF-β1 in hepatocellular carcinoma. BMC Cancer. 2018;18(1):1179. DOI: 10.1186/s12885-018-5016-zZhang H.W., Wang E.W., Li L.X., Yi S.H., Li L.C., Xu F.L., Wang D.L., Wu Y.Z. et al. A regulatory loop involving miR-29c and Sp1 elevates the TGF-β1 mediated epithelial-to-mesenchymal transition in lung cancer. Oncotarget. 2016;7(52):85905-85916. DOI: 10.18632/oncotarget.13137Zhang H.W., Wang E.W., Li L.X., Yi S.H., Li L.C., Xu F.L., Wang D.L., Wu Y.Z. et al. A regulatory loop involving miR-29c and Sp1 elevates the TGF-β1 mediated epithelial-to-mesenchymal transition in lung cancer. Oncotarget. 2016;7(52):85905-85916. DOI: 10.18632/oncotarget.13137Zhang J., Liu W., Shen F., Ma X., Liu X., Tian F., Zeng W., Xi X. et al. The activation of microRNA-520h-associated TGF-β1/c-Myb/Smad7 axis promotes epithelial ovarian cancer progression. Cell Death Dis. 2018;9(9):884. DOI: 10.1038/s41419-018-0946-6Zhang J., Liu W., Shen F., Ma X., Liu X., Tian F., Zeng W., Xi X. et al. The activation of microRNA-520h-associated TGF-β1/c-Myb/Smad7 axis promotes epithelial ovarian cancer progression. Cell Death Dis. 2018;9(9):884. DOI: 10.1038/s41419-018-0946-6Zhang N., Bi X., Zeng Y., Zhu Y., Zhang Z., Liu Y., Wang J., Li X. et al. TGF-β1 promotes the migration and invasion of bladder carcinoma cells by increasing fascin1 expression. Oncol Rep. 2016;36(2):977-983. DOI: 10.3892/or.2016.4889Zhang N., Bi X., Zeng Y., Zhu Y., Zhang Z., Liu Y., Wang J., Li X. et al. TGF-β1 promotes the migration and invasion of bladder carcinoma cells by increasing fascin1 expression. Oncol Rep. 2016;36(2):977-983. DOI: 10.3892/or.2016.4889Zhang X., Liu L., Deng X., Li D., Cai H., Ma Y., Jia C., Wu B. et al. MicroRNA 483-3p targets Pard3 to potentiate TGF-β1-induced cell migration, invasion, and epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Oncogene. 2019;38(5):699-715. DOI: 10.1038/s41388-018-0447-1Zhang X., Liu L., Deng X., Li D., Cai H., Ma Y., Jia C., Wu B. et al. MicroRNA 483-3p targets Pard3 to potentiate TGF-β1-induced cell migration, invasion, and epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Oncogene. 2019;38(5):699-715. DOI: 10.1038/s41388-018-0447-1Zhang Y., Alexander P.B., Wang X.F. TGF-β Family Signaling in the Control of Cell Proliferation and Survival. Cold Spring Harb Perspect Biol. 2017;9(4):a022145. DOI: 10.1101/cshperspect.a022145Zhang Y., Alexander P.B., Wang X.F. TGF-β Family Signaling in the Control of Cell Proliferation and Survival. Cold Spring Harb Perspect Biol. 2017;9(4):a022145. DOI: 10.1101/cshperspect.a022145Zhang Y., Li B., Li X., Tan H., Cheng D., Shi H. An imaging target TGF-β1 for hepatocellular carcinoma in mice. Hell J Nucl Med. 2017;20(1):76-78. DOI: 10.1967/s002449910510Zhang Y., Li B., Li X., Tan H., Cheng D., Shi H. An imaging target TGF-β1 for hepatocellular carcinoma in mice. Hell J Nucl Med. 2017;20(1):76-78. DOI: 10.1967/s002449910510Zhang Y., Shi K., Liu H., Chen W., Luo Y., Wei X., Wu Z. miR-4458 inhibits the epithelial-mesenchymal transition of hepatocellular carcinoma cells by suppressing the TGF-β signaling pathway via targeting TGFBR1. Acta Biochim Biophys Sin (Shanghai). 2020;52(5):554-562. DOI: 10.1093/abbs/gmaa029Zhang Y., Shi K., Liu H., Chen W., Luo Y., Wei X., Wu Z. miR-4458 inhibits the epithelial-mesenchymal transition of hepatocellular carcinoma cells by suppressing the TGF-β signaling pathway via targeting TGFBR1. Acta Biochim Biophys Sin (Shanghai). 2020;52(5):554-562. DOI: 10.1093/abbs/gmaa029

The authors declare that there are no conflicts of interest present.